Biogen
Prix: 200.05Entreprise et modèle économique
Biogen is a biotechnology company focused on discovering, developing, and delivering innovative therapies for neurological diseases. Its core products include treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. Major business segments encompass neuroscience and rare diseases, with primary revenue sources derived from product sales and royalties. The company is recognized for its research and development efforts in the healthcare sector.
Profil d’investissement
The investment profile of Biogen is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The stock may appeal to those seeking long-term capital appreciation rather than immediate income. Its moderate volatility suggests a balanced risk approach, suitable for investors with a medium to long-term horizon.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 9.37 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- 8.7% ↑
- Surprise BPA
- 17.0% meilleur que prévu
- Volatilité 20 j
- 1.8% stable
Impact de la prévision
positifSuivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-05-28 02:36 | Conserver | Acheter | Strong EPS growth and positive momentum indicators. |
| 2026-05-20 02:36 | Acheter | Conserver | Mixed performance; cautious outlook amid market uncertainty. |
| 2026-05-08 15:04 | — | Acheter | Strong EPS growth and positive momentum indicators. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-06-08 10:32 | Needham | Note relevée | — → 255 | 195.34 |
| 2026-05-27 09:42 | RBC Capital | Objectif relevé | — → 227 | 193.08 |
| 2026-05-15 10:33 | Piper Sandler | Objectif relevé | 214 → 225 | 191.37 |
Rien pour le moment